Ηπατοκυτταρικό νεόπλασμα/Μεταμόσχευση

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

30 Οκτωβρίου 2023

Shukui Q., Minshan C., Ann-Lii C. et al. for the IMbrave050 investigators The Lancet, October 2023 (published online first) doi: (https://doi.org/10.1016/S0140-6736(23)01796-8) Δείτε ΕΔΩ το άρθρο.

Περισσότερα »

Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection

8 Οκτωβρίου 2023

Pelizzaro F., Trevisani F., Simeon V. et al. for the Italian Liver Cancer (ITA.LI.CA.) group Liver International 2023, Sep 27. doi: https://doi.org/10.1111/liv.15719 Δείτε ΕΔΩ την

Περισσότερα »

Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures

28 Σεπτεμβρίου 2023

Sean Wharton, M.D., Thomas Blevins, M.D., Lisa Connery, M.D., et al for the GZGI Investigators* N Engl J Med 2023; 389:877-888DOI: 10.1056/NEJMoa2302392 Δείτε ΕΔΩ την

Περισσότερα »

Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals

26 Σεπτεμβρίου 2023

Tatsuya Minami †, Masaya Sato †, Hidenori Toyoda, et alJournal of Hepatology 2023. vol. 79, issue 4, p1006-1014, October 2023(doi: https://doi.org/10.1016/j.jhep.2023.05.042) Δείτε ΕΔΩ την περίληψη

Περισσότερα »